Adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, was $1.06 for the fourth quarter of 2008, an increase of 6% compared to $1 for the fourth quarter of 2007.
Full-year 2008 adjusted EPS, excluding stock option expense and certain other expenses, were $4.55 versus $4.29 in 2007, a 6% increase. Full-year 2008 adjusted net income, excluding stock option expense and certain other expenses, was $4.88 billion versus $4.80 billion in 2007, a 2% increase.
Total revenue of $3.75 billion in the fourth quarter of 2008 was essentially flat compared to $3.74 billion in the fourth quarter of 2007. For the full year 2008, total revenue increased 2% to $15 billion from $14.77 billion in 2007, the company said.
Kevin Sharer, chairman and CEO of Amgen, said: “I am proud of Amgen’s performance in 2008 and excited about our prospects in 2009 and beyond. While Amgen faces a range of challenges in today’s environment, I am confident we are ready.”